Invivyd reports VYD2311 topline safety edge over mRNA COVID vaccine in LIBERTY trial
The Phase 3 LIBERTY study met all primary and secondary endpoints, and Invivyd plans a BLA filing under the Accelerated Approval Program.
SEC filing
Latest
3 stories
Tuesday, September 29
Tuesday, September 1
Invivyd names Chairman Marc Elia as CEO, adds board member ahead of VYD2311 data
The company also elevated Ajay Royan to lead independent director and appointed Ian Sheffield to the board as VYD2311 trial results near completion.
SEC filing
Thursday, August 13
Invivyd completes enrollment in two VYD2311 pivotal trials, reports Q2 2026 results
LIBERTY is fully dosed with data due late Q3 2026, while DECLARATION enrollment is complete with data planned later in Q3 2026, as PEMGARDA revenue grew 21%.
SEC filing